Preliminary Amendment Serial No.: 09/338,063

Page 2 of 8

## In the Claims:

Please cancel claims 32-35.

Please introduce new claims 37-49 as follows:

1--3. (New) An isolated monoclonal antibody produced by a hybridoma selected from the group consisting of A1G5 having Accession No. FERM BP-7441, D2F4 having Accession No. FERM BP-7442, and E3H8 having Accession No. FERM BP-7443 recognizing osteoclastogenesis inhibitory factor.

2 38. (New) The isolated monoclonal antibody of claim 31 wherein said hybridoma is A1G5 having Accession No. FERM BP-7441.

39. (New) The isolated monoclonal antibody of claim 39 wherein said hybridoma is D2F4 having Accession No. FERM BP-7442.

40. (New) The isolated monoclonal antibody of claim 37 wherein said hybridoma is E3H8 having Accession No. FERM BP-7443.

(New) An assay kit for determination of osteoclastogenesis inhibitory factor protein concentration, the assay kit comprising at least one monoclonal antibody produced by a hybridoma selected from the group consisting of A1G5 having Accession No. FERM BP-7441, D2F4 having Accession No. FERM BP-7442, and E3H8 having Accession No. FERM BP-7443.

6 AZ. (New) The assay kit of claim A wherein said hybridoma is A1G5 having Accession No. FERM BP-7441.

1 43. (New) The assay kit of claim 41 wherein said hybridoma is D2F4 having Accession No. FERM BP-7442.

8 44. (New) The assay kit of claim 41 wherein said hybridoma is E3H8 having Accession No. FERM BP-7443.

A hubridoma 9 A5. (New) Hybridoma selected from the group consisting of A1G5 having Accession No. FERM BP-7441, D2F4 having Accession No. FERM BP-7442, and E3H8 having Accession No. FERM BP-7443.

Preliminary Amendment Serial No.: 09/338,063 Page 3 of 8

10 A6. (New) The hybridoma of claim 45 wherein said hybridoma is A1G5 having Accession No. FERM BP-7441.

No. FERM BP-7442.

12 48. (New) The hybridoma of claim 45 wherein said hybridoma is E3H8 having Accession No. FERM BP-7443.

49. (New) A monoclonal antibody which binds to osteoclastogenesis inhibitory factor protein, comprising:

- (a) molecular weights as determined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) of approximately 60 kD under reducing conditions, and approximately 60 kD (a monomer) and 120 kD (a homodimer) under non-reducing conditions;
- (b) high affinity to cation-exchange resins and heparin derivatives;
- (c) inhibitory activity for osteoclast differentiation and/or maturation, wherein said activity is decreased by heating said protein at about 70°C for about 10 min. or at about 56°C for about 30 min., and wherein said activity is lost by heating at about 90°C for about 10 min.; and
- (d) an internal amino acid sequence as provided in SEQ. ID NOS. 1, 2 or 3;

wherein said monoclonal antibody comprises a binding site selected from the group consisting of A1GF having Accession No. FERM BP-7441, D2F4 having Accession No. FERM BP-7442, and E3H8 having Accession No. FERM BP-7443 binding sites.--

## **REMARKS**

## Status of the Claims

Claims 32-35 are pending in the above-referenced application. Claims 37-49 are introduced herein. Claims 32-35 are canceled. Upon entry of this paper, claims 37-49 will be pending in the instant application.